Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology

Acquisition adds ABS-011, an investigational Phase 2b gallium-68-labeled PET radiodiagnostic tracer targeting HER2 Transaction strengthens Curium radiodiagnostic capabilities and oncology footprint, including in breast and gastric cancers BOSTON and LIEGE, Belgium, Aug. 10, 2026 (GLOBE NEWSWIRE) — Curium™ a leading global radiopharmaceutical company, announced that it has completed the acquisition of Abscint SA, a Belgian […]